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LETTER TO THE EDITOR
Prevalence of Multidrug-Resistant and Extensively 
Drug-Resistant Tuberculosis in Patients with Pulmo-
nary Tuberculosis in Zahedan, Southeastern Iran 
 
 
Dear Editor, 
Tuberculosis (TB) is responsible for a large portion of 
morbidity and mortality worldwide. According to 
WHO report, tuberculosis is responsible for at least 2 
million deaths per year, so 90% of these occurring in 
developing countries.
1,2 Recently, it has been shown 
that multidrug-resistance (MDR) and extensively drug-
resistant tuberculosis (XDR-TB) are the most im-
portant factors cause death in patients with tuberculo-
sis.
3,4 Drug resistance of M tuberculosis has been im-
plicated in many etiologies such as inadequate and in-
complete treatment, host genetic factors and, HIV in-
fection.
5-8 The long duration of treatment, large amount 
of anti-TB drugs and their gastrointestinal side effects, 
are the most important causes of noncompliance in 
patients with TB.
4 MDR-TB (when resistance to isoni-
azid and rifampicin appears in combination), increases 
the numbers of individuals who need treatment with 
second-line drugs worldwide.
9,10 After developments 
of MDR-TB, the development of resistance to second 
line drugs was another problem.
5 XDR-TB is a form of 
TB caused by bacteria that are resistant to the most 
effective anti-TB drugs. XDR explained by resistance 
to both rifampin and isoniazid, as well as to fluoro-
quinolones plus an injectable agent and Pre–XDR TB 
isolates are multidrug resistant bacilli which are re-
sistant to either a fluoroquinolone or an injectable 
agent, but not both.
11 Some believe that XDR-TB 
strains have emerged from the mismanagement of mul-
tidrug-resistant TB  and once created, can spread from 
one person to another.
7,12 TB and  drug resistant tuber-
culosis is also a serious public health problem in Iran 
as other developing countries. According to the World 
Health Organization, the estimated incidence rate of 
TB in Iran is 28 cases per 100,000 population.
2,6 In a 
report from Southest of Iran,among patients with PTB 
in Zahedan, where  the incidence rate of TB is higher 
than other regions of Iran,16% of patients with PTB 
had MDR TB.
9 XDR-TB is higher in patients with 
MDR-TB and mortality in XDR-TB is higher than 
MDR-TB.
7 Recent report in Iran showed that 5.3% of 
patients with PTB had MDR-TB and of these patients, 
10.9% had XDR-TB.
7 Since, there were few reports 
about MDR-TB and no any data about the prevalence 
of XDR-TB in Zahedan, we decided to evaluate them. 
From January 2007 to January 2008, we evaluated 
all patients with a positive sputum culture who referred 
to our hospital (Research Center for Infectious Diseas-
es and Tropical Medicine). First, all patients who had 
clinical signs and symptoms suggestive of PTB were 
enrolled. These patients were asked to participate in 
our study. If they accepted, they underwent testing in-
cluding Ziehl-Neelsen staining and culture. Patients 
who subsequently were culture-negative for Mycobac-
terium tuberculosis were withdrawn from the study. 
Then, we analyzed all culture-positive cases of Myco-
bacterium tuberculosis infection referred to our TB 
center. Primary isolation and culture of Mycobacterium 
isolates, after NaOH-N-acetylcysteine was done in 
conformity with standard solid-culture procedures.
13 
All isolates were identified as M. tuberculosis complex 
with use of standard biochemical tests, including niacin 
activity, production of catalase and nitrate reduction, as 
well as the registration of pigment production  and 
growth rate. Drug susceptibility testing against isonia-
zid and rifampicin was done by the proportional meth-
od on Lo¨wenstein-Jensen media at a concentration of 
0.1 and 0.001 mg/mL.
14 Drug-susceptibility testing 
against second-line drugs (amikacin, kanamycin, cap-
reomycin, ciprofloxacin, levofloxain) was carried out 
using 2 critical proportions of 0.1 and 0.001. All of 
these drugs were purchased from glaxo Chemical. 
Clinical and Epidemiological Information collected 
from patients with confirmed cases of TB by trained 
technicians using standard questionnaires. Information 
obtained on sex, age, previous history of TB, present 
address, and associated medical data such as chest 
radiograph findings and presence of HIV infection. 
Patients also required to have drug-susceptibility test 
results that showed  resistance to isoniazid and ri-
fampin (as MDR-TB), as well as chest radiograph 
findings and clinical signs and symptoms that were 
compatible with PTB. Statistical analysis was per-
formed using SPSS, version 11. Data were analyzed 
by Chi-Square test and p<0.05 was considered sig-
nificant. Metanat et al. 
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This prospective study was conducted using a total 
of eighty eight patients (40% male, 60% female) with 
positive sputum culture for M. tuberculosis complex. 
The patients aged between 15 and 94 years. 90% of 
patients were Iranian and 10% wer Afghan. 12.2% of 
our patients had MDR-TB (3 females; 6 males) and 
one subject with pre-XDR-TB (resistant to capreo-
mycin) identified. No case had XDR-TB. 8% of cul-
ture positive patients had a negative sputum smear 
and two cases had HIV infection. Ten patients (8.8%) 
had a past history of treatment for tuberculosis. 
Among previously treated patients, 44% had MDR-
TB. Among patients who had received a new diagno-
sis, 10% had MDR-TB.  
Our results showed that 12.2% of our patients had 
MDR-TB. One patient with pre- XDR-TB (capreo-
mycin resistanse) identified; and there was no case of 
XDR-TB. Tuberculosis is a serious public health 
problem in Iran as other developing countries and 
MDR-TB is a very important and serious health prob-
lem among patients with tuberculosis.
9,10 Extensively 
drug-resistant tuberculosis has also recently emerged 
as a global health problem, threatening the success of 
TB control programs in the world.
7,15,16 There are 
many reports which show MDR and XDR-TB are 
increasing worldwide. Recent studies in Iran also 
showed that both MDR and XDR-TB were increasing 
especially among  patients  treated  within  inappro-
priate regimens or when patients became selectively 
non-compliant by not taking all of the 3 or 4 
drugs.
4,9,10 Masjedi et al. reported  results of suscepti-
bility to first-line drugs performed for 1284 Mycobac-
terium tuberculosis isolates who  were referred to the 
National Research Institute of Tuberculosis and Lung 
Diseases (Tehran, Iran) for treatment and diagnosis 
from 2003 to 2005. Subsequently, the strains which 
were identified as multidrug-resistant M. tuberculosis 
(113 isolates) were subjected to susceptibility testing 
for second line drugs. A total of 12 (10.9%) of 113 
multidrug-resistant M. tuberculosis strains were XDR 
M. tuberculosis.
7 Shamimi and his colleagues report-
ed 2% of 548 patients had MDR-TB.
17 Another study 
in Southeast Iran by Naserpour and  colleages showed 
that 16% of patients with PTB had MDR-TB.
8 There 
was no any XDR-TB among patients in these two 
recent studies. A global survey in reference laborato-
ries for TB isolates during 2000–2004 identified 
XDR-TB in 17 countries and estimated that10% of 
the sampled multidrug-resistant (MDR) TB strains 
were XDR.
18 A study in California during 1993–
2006, identified 18 XDR-TB cases who had poor out-
comes. None of the patients in California with XDR-
TB had AIDS.
19  
In conclusion, 12.2% of patients had MDR-TB. 
There was no patient with XDR-TB in our study. We 
recommend drug-susceptibility testing on the first-
line drugs in any patient with tuberculosis in the be-
ginning of treatment. 
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